What Would Be The Tenacity Of The Interventional Pulmonology Market In The Next 10 Years?
Interventional pulmonology is an area of pulmonary medicine that deals specifically with minimally invasive endoscopic and percutaneous procedures for the diagnosis and treatment of neoplastic as well as non-neoplastic diseases of the airways, lungs, and pleura. Rise in the number of COPD cases across the world is expected to boost demand over the coming years. Need for faster recovery time and reduced pain during procedures and surgeries for respiratory disorders has strengthened the market. Leading manufacturers of interventional pulmonology devices are focusing on geographical expansion to increase revenue and add new repair and service centers in emerging countries through the acquisition of local players.
Various awareness programs have been initiated by healthcare providers and health organizations/societies such as environmental programs, medication maintenance programs, and online education programs for public and healthcare professionals across the globe to control asthma, COPD, and other respiratory diseases. Major companies such as Boston Scientific Corporation, Olympus Corporation, and FUJIFILM Corporation, besides others, are focused on spreading awareness regarding respiratory diseases.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/12544
Companies covered in Interventional Pulmonology Market Report
Boston Scientific Corporation
Becton, Dickinson and Company
Smiths Group Plc
Clarus Medical LLC
Huger Medical Instrument Co. Ltd
Taewoong Medical Co. Ltd.
Shanghai AoHua Photoelectricity Endoscope Co., Ltd
Richard Wolf Corporation
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/12544
As per Persistence Market Research analysis, the global interventional pulmonology market is expected to exhibit a CAGR of more than 4% over the forecast period (2021 – 2031).
Key Takeaways from Study
IP diagnostic devices are expected to hold maximum revenue share under products.
Lung cancer is projected to be the dominant segment among indications, in terms of revenue. The segment accounted for 26.6% share in 2020.
The U.S., followed by Europe, is expected to hold substantial revenue share in the global interventional pulmonology market.
Emerging economies such as China, India, Brazil, Mexico, and South Africa have a large COPD patient pool, and rising disposable income of patients with increased healthcare expenditure would encourage interventional pulmonology device manufacturers to enter these markets.
The interventional pulmonology space faced adverse effects due to...
Do you already have an account? Log in here